The Somogyi hypothesis: a parallelism with Michael Somogyi's life
- PMID: 39718705
- PMCID: PMC12339641
- DOI: 10.1007/s42000-024-00624-0
The Somogyi hypothesis: a parallelism with Michael Somogyi's life
Abstract
Michael Somogyi (Somogyi Mihály, 1883-1971) was a Hungarian biochemist who developed his scientific career in Europe and, primarily, the United States. He gave the name to the eponymous Somogyi effect or Somogyi hypothesis (in short, rebound hyperglycemia after insulin-induced hypoglycemia, particularly nocturnal), which was an axiom in the treatment of diabetes for decades. Although it is currently debated whether the Somogyi hypothesis is a real or relevant phenomenon in patients with diabetes, Somogyi's other significant career achievements are often overlooked. The aim of this historical note is to compile and highlight Michael Somogyi's scientific achievements. Michael Somogyi was a pioneer in the administration of insulin to patients with diabetes in the United States and in devising a method for insulin production. In addition, he highlighted the relevance of diet in patients with diabetes and was one of the first chemists to be integrated into clinical laboratories. There, Somogyi standardized long-lasting biological determinations, such as that of amylase, and he was one of the first scientists to combine basic research (from his training as a biochemist) with clinical research in close collaboration with physicians caring for patients, which is what we know today as translational research. Notably, the trajectory of his scientific career resembles the rebound effect of Somogyi's hypothesis: after reaching a low point of work activity well below his professional qualifications, his effort and tenacity led to the aforementioned achievements, and he became part of the history of hypoglycemia and diabetes.
Keywords: Diabetes; Hypoglycemia; Insulin; Somogyi.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures



Similar articles
-
Oral anti-diabetic agents for women with established diabetes/impaired glucose tolerance or previous gestational diabetes planning pregnancy, or pregnant women with pre-existing diabetes.Cochrane Database Syst Rev. 2017 Oct 18;10(10):CD007724. doi: 10.1002/14651858.CD007724.pub3. Cochrane Database Syst Rev. 2017. PMID: 29045765 Free PMC article.
-
Insulin and oral agents for managing cystic fibrosis-related diabetes.Cochrane Database Syst Rev. 2016 Apr 18;4:CD004730. doi: 10.1002/14651858.CD004730.pub4. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 Oct 19;10:CD004730. doi: 10.1002/14651858.CD004730.pub5. PMID: 27087121 Updated.
-
Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.Health Technol Assess. 2004 Nov;8(45):iii, 1-57. doi: 10.3310/hta8450. Health Technol Assess. 2004. PMID: 15525480
-
Insulin for the treatment of women with gestational diabetes.Cochrane Database Syst Rev. 2017 Nov 5;11(11):CD012037. doi: 10.1002/14651858.CD012037.pub2. Cochrane Database Syst Rev. 2017. PMID: 29103210 Free PMC article.
-
Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.Cochrane Database Syst Rev. 2016 Jun 30;2016(6):CD012161. doi: 10.1002/14651858.CD012161. Cochrane Database Syst Rev. 2016. PMID: 27362975 Free PMC article.
Cited by
-
GLP-1 agonists on a roll: from obesity to psoriasis - an elixir to watch!Hormones (Athens). 2025 Jun;24(2):287-289. doi: 10.1007/s42000-025-00697-5. Hormones (Athens). 2025. PMID: 40699508 No abstract available.
-
Duration of type 1 diabetes and glycaemic control in adults: A nonlinear relationship.Diabetes Obes Metab. 2025 Jul;27(7):4001-4006. doi: 10.1111/dom.16392. Epub 2025 Apr 14. Diabetes Obes Metab. 2025. PMID: 40223475 Free PMC article. No abstract available.
References
-
- Anonymous (2024) Südburgenland erleben. https://www.sued-burgenland.com/reinersdorf.htm. Accessed August 28 2024
-
- Soltész G (2022) Somogyi Mihály (1883–1971). Diabetologia Hungarica 30:223–226
-
- Soltész G (2002) Michael Somogyi. The man behind “the phenomenon.” Diabetologia Hungarica 10(Suppl 2):5–7
-
- Szállási A (2001) Egy ismert effektus alig ismert névadója: Somogyi Mihály (1883–1971) [A hardly known eponym of a well-known effect: Mihály Somogyi (1883–1971)]. Orv Hetil 142:1749–1750 - PubMed
-
- Jermendy G (2002) Somogyi emléke a diabetológiában [Memory of Dr. Somogyi in diabetology]. Orv Hetil 143:532 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical